Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1841. Effects of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom

or delay of progression of diabetic nephropathy to end-stage renal disease (ESRD) in patients with Type 2 diabetes mellitus (DM-2) and nephropathy. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with DM-2 and nephropathy. Inclusion and exclusion criteria may be found in the primary publication. Setting The setting was primary care. The economic study was carried out in the UK. Dates to which data (...) was reduced by 50%). Authors' conclusions A losartan-based regimen in patients with Type 2 diabetes mellitus (DM-2) and nephropathy was cost-saving from the perspective of the National Health Service (NHS) in the UK because it reduced the incidence of end-stage renal disease (ESRD) in comparison with a non angiotensin-converting enzyme inhibitor or non angiotensin II antagonist antihypertensive regimen. CRD COMMENTARY - Selection of comparators The authors justified the choice of the comparators, which

2005 NHS Economic Evaluation Database.

1842. The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance

The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance Herman W H, Thomas M P, Hoerger T J, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman R F (...) , Ackermann R T, Engelgau M M, Ratner R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two interventions for the prevention of Type 2 diabetes in adults with impaired glucose tolerance were examined. The interventions were intensive

2005 NHS Economic Evaluation Database.

1843. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Lechleitner M, Roden M, Haehling E (...) , Mueller M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of insulin glargine (IG) in combination with oral antidiabetic drugs (OADs) for the treatment of patients with Type 2 diabetes mellitus. Type of intervention Treatment

2005 NHS Economic Evaluation Database.

1844. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria Palmer A J, Annemans L, Roze S (...) of end-stage renal disease (ESRD) in Type 2 diabetes patients with hypertension and microalbuminuria. The comparator was standard care alone. Standard antihypertensive medications refer to those required to achieve a target blood pressure of less than 135/85 mmHg, excluding angiotensin-converting enzyme (ACE) inhibitors, other angiotensin II receptor antagonists, and dihydropyridine calcium-channel blockers. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis

2005 NHS Economic Evaluation Database.

1845. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

1846. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes

Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes Di Loreto C, Fanelli C, Lucidi P, Murdolo G, De Cicco A, Parlanti N, Ranchelli A, Fatone C, Taglioni C, Santeusanio F, De Feo P Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions examined in the study were different levels of intensity of an exercise counselling intervention supporting moderate voluntary aerobic physical activity for patients with type 2 diabetes

2005 NHS Economic Evaluation Database.

1847. The efficacy and cost of alternative strategies for systematic screening for Type 2 diabetes in the U.S. population 45 - 74 years of age

The efficacy and cost of alternative strategies for systematic screening for Type 2 diabetes in the U.S. population 45 - 74 years of age The efficacy and cost of alternative strategies for systematic screening for Type 2 diabetes in the U.S. population 45 - 74 years of age The efficacy and cost of alternative strategies for systematic screening for Type 2 diabetes in the U.S. population 45 - 74 years of age Johnson S L, Tabaei B P, Herman W H Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several screening strategies for Type 2 diabetes were examined: screening with a random plasma glucose (RPG) cut point of 100 mg/dL, a highly sensitive test; screening with an RPG cut point of 160 mg/dL, a highly specific test

2005 NHS Economic Evaluation Database.

1848. Multisystemic treatment of poorly controlled type 1 diabetes: effects on medical resource utilization

Multisystemic treatment of poorly controlled type 1 diabetes: effects on medical resource utilization Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

1849. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin (...) glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Valentine W J, Palmer A J, Lammert M, Nicklasson L, Foos V, Roze S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of biphasic

2005 NHS Economic Evaluation Database.

1850. A 3-year prospective randomized controlled clinical trial of group care in type 1 diabetes

the study in other settings or in reflation exercises. Other issues The authors made appropriate comparisons of their findings with those from other studies. In particular, they made comparisons with their earlier study on Type 2 diabetics. The study was carried out in a single centre and the issue of generalisability to other settings was addressed. The authors did not present their results selectively. Implications of the study Group care may represent a model in which education merges with clinical (...) A 3-year prospective randomized controlled clinical trial of group care in type 1 diabetes A 3-year prospective randomized controlled clinical trial of group care in type 1 diabetes A 3-year prospective randomized controlled clinical trial of group care in type 1 diabetes Trento M, Passera P, Borgo E, Tomalino M, Bajardi M, Brescianini A, Tomelini M, Giuliano S, Cavallo F, Miselli V, Bondonio P, Porta M Record Status This is a critical abstract of an economic evaluation that meets the criteria

2005 NHS Economic Evaluation Database.

1851. Screening for type 2 diabetes mellitus to prevent vascular complications Full Text available with Trip Pro

Screening for type 2 diabetes mellitus to prevent vascular complications Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Synopsis D Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care Denice S. Feig , Valerie (...) A. Palda , Lorraine Lipscombe and ; with The Canadian Task Force on Preventive Health Care Valerie A. Palda Lorraine Lipscombe © 2005 Canadian Medical Association or its licensors Recommendations There is fair evidence to recommend screening adults with hypertension for type 2 diabetes mellitus to prevent cardiovascular events and death (grade B recommendation). There is fair evidence to recommend screening adults with hyperlipidemia for type 2 diabetes to prevent cardiovascular events and death (grade

2005 CPG Infobase

1852. Type 2 diabetes: principles of pathogenesis and therapy. Full Text available with Trip Pro

Type 2 diabetes: principles of pathogenesis and therapy. Type 2 diabetes mellitus has become an epidemic, and virtually no physician is without patients who have the disease. Whereas insulin insensitivity is an early phenomenon partly related to obesity, pancreas beta-cell function declines gradually over time already before the onset of clinical hyperglycaemia. Several mechanisms have been proposed, including increased non-esterified fatty acids, inflammatory cytokines, adipokines

2005 Lancet

1853. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. (Abstract)

Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Diabetes mellitus is the fifth leading cause of death in the United States; 17 million people are affected. Liver disease is one of the leading causes of death in persons with type 2 diabetes. The standardized mortality rate for death from liver disease is greater than that for cardiovascular disease. The spectrum of liver disease in type 2 diabetes ranges from nonalcoholic fatty liver disease to cirrhosis and hepatocellular

2004 Annals of Internal Medicine

1854. An intensive, target driven intervention reduced cardiovascular and microvascular events in patients with type 2 diabetes and microalbuminuria Full Text available with Trip Pro

An intensive, target driven intervention reduced cardiovascular and microvascular events in patients with type 2 diabetes and microalbuminuria An intensive, target driven intervention reduced cardiovascular and microvascular events in patients with type 2 diabetes and microalbuminuria | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) with type 2 diabetes and microalbuminuria Article Text Treatment An intensive, target driven intervention reduced cardiovascular and microvascular events in patients with type 2 diabetes and microalbuminuria Free Mary van Soeren , RN, ACNP, PhD Statistics from Altmetric.com Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383 –93 QUESTION: In patients with type 2 diabetes and microalbuminuria, what

2004 Evidence-Based Nursing

1855. Treatment of hypertension reduces risk of complications in type 2 diabetes Full Text available with Trip Pro

Treatment of hypertension reduces risk of complications in type 2 diabetes Treatment of hypertension reduces risk of complications in type 2 diabetes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Treatment of hypertension reduces risk of complications in type 2 diabetes Article Text Treatment Treatment of hypertension reduces risk of complications in type 2 diabetes Free Katie Weinger , RN, EdD , James Rosenzweig , MD Statistics from

2004 Evidence-Based Nursing

1856. An internet behavioural counselling weight loss programme reduced weight and BMI in patients at risk of type 2 diabetes Full Text available with Trip Pro

An internet behavioural counselling weight loss programme reduced weight and BMI in patients at risk of type 2 diabetes An internet behavioural counselling weight loss programme reduced weight and BMI in patients at risk of type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An internet behavioural counselling weight loss programme reduced weight and BMI in patients at risk of type 2 diabetes Article Text Therapeutics

2004 Evidence-Based Medicine

1857. Relationship of physical activity vs body mass index with type 2 diabetes in women. Full Text available with Trip Pro

Relationship of physical activity vs body mass index with type 2 diabetes in women. Physical inactivity and body mass index (BMI) are established independent risk factors in the development of type 2 diabetes; however, their comparative importance and joint relationship with diabetes are unclear.To examine the relative contributions and joint association of physical activity and BMI with diabetes.Prospective cohort study of 37 878 women free of cardiovascular disease, cancer, and diabetes (...) with 6.9 years of mean follow-up. Weight, height, and recreational activities were reported at study entry. Normal weight was defined as a BMI of less than 25; overweight, 25 to less than 30; and obese, 30 or higher. Active was defined as expending more than 1000 kcal on recreational activities per week.Incident type 2 diabetes, defined as a new self-reported diagnosis of diabetes.During the follow-up, 1361 cases of incident diabetes occurred. Individually, BMI and physical activity were significant

2004 JAMA

1858. An intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria Full Text available with Trip Pro

reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria Free Sean F Dinneen , MD, FRCPI , Simon Griffin , MSc, DM, FRCGP Statistics from Altmetric.com ( 2003 ) N Engl J Med 348 , 383 . Gaede P, Vedel P, Larsen N, et al. . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. . ; . : . –93 . QUESTION: In patients with type 2 diabetes and microalbuminuria, is a targeted intensive multifactorial intervention more effective than (...) An intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria An intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2004 Evidence-Based Medicine

1859. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. Full Text available with Trip Pro

Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. Sugar-sweetened beverages like soft drinks and fruit punches contain large amounts of readily absorbable sugars and may contribute to weight gain and an increased risk of type 2 diabetes, but these relationships have been minimally addressed in adults.To examine the association between consumption of sugar-sweetened beverages and weight change and risk of type 2 diabetes in women.Prospective (...) cohort analyses conducted from 1991 to 1999 among women in the Nurses' Health Study II. The diabetes analysis included 91,249 women free of diabetes and other major chronic diseases at baseline in 1991. The weight change analysis included 51,603 women for whom complete dietary information and body weight were ascertained in 1991, 1995, and 1999. We identified 741 incident cases of confirmed type 2 diabetes during 716,300 person-years of follow-up.Weight gain and incidence of type 2 diabetes.Those

2004 JAMA

1860. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. (Abstract)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily (...) for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol.2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following

2004 Lancet Controlled trial quality: predicted high